A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (Q43052325)

13 November 2017

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (English)

1 reference

13 November 2017

1 reference

3

1 reference

13 November 2017

6

I Ray-Coquard

1 reference

13 November 2017

P Schöffski

1

1 reference

13 November 2017

P Reichardt

2

1 reference

13 November 2017

H Dumez

4

1 reference

13 November 2017

J A Morgan

5

1 reference

13 November 2017

N Hollaender

7

1 reference

13 November 2017

A Jappe

8

1 reference

13 November 2017

G D Demetri

9

1 reference

13 November 2017

27 May 2010

1 reference

13 November 2017

1 reference

13 November 2017

21

1 reference

13 November 2017

10

1 reference

13 November 2017

1990-1998

1 reference

Gastrointestinal stromal tumor (GIST).

13 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Novel approaches to imatinib- and sunitinib-resistant GIST.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

The biology behind mTOR inhibition in sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

The expanding TOR signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ076

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ076

1 reference

13 November 2017

1 reference